Outcomes of Phase I Trial of Patients With Recurrent Head and Neck Squamous Cell Carcinoma Treated With Re-Irradiation With Stereotactic Body Radiation Therapy and Concurrent Cisplatin
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS(2021)
Abstract
Patients with recurrent head and neck cancer typically present with advanced, unresectable disease, and therefore have limited definitive treatment options. This phase I study demonstrates that SBRT with concurrent Cisplatin provides reasonable locoregional control and overall survival with radiation doses of 40 Gy.
MoreTranslated text
Key words
stereotactic body re-irradiation therapy,neck squamous cell carcinoma,re-irradiation therapy,squamous cell carcinoma,recurrent head
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined